{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:18:44Z","timestamp":1783955924006,"version":"3.55.0"},"reference-count":54,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Circulating Tumor Cells (CTCs) are a potential source of metastases and\nrelapses. The data on molecular characteristics of Ovarian Cancer (OC) CTCs are limited.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aims to assess the TGF\u03b2, CXCL2, VEGFA and ERCC1 expressions in two\nOC CTC subpopulations before and during chemotherapy (CT), and their relation to clinical characteristics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Two CTCs subpopulations (EpCAM+CK18+E-cadherin+; EpCAM+CK18+Vimentin+)\nwere enriched using immunomagnetic separation before treatment and after 3 cycles of platinumcontaining\nCT. The expression of mRNA was assessed using RT-qPCR.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The study included 31 I-IV stage OC patients. During CT, TGF\u03b2 levels increased in both\nfractions (p=0.054) compared with the initial levels. ERCC1 expression in E-cadherin+ CTCs was\nhigher during neoadjuvant than adjuvant CT (p=0.004). CXCL2 level in E-cadherin+ CTCs increased\n(p=0.038) during neoadjuvant CT compared with the initial. TGF-\u03b2 expression in vimentin+\nCTCs during CT was negatively correlated to disease stage (p=0.003). Principal component\nanalysis before CT revealed a component combining VEGFA, TGF\u03b2, CXCL2, and a component\nwith ERCC1 and VEGFA; during CT, component 1 contained ERCC1 and VEGFA, and component\n2 - TGF\u03b2 and CXCL2 in both fractions. Increased ERCC1 expression in E-cadherin+ CTCs\nduring CT was associated with decreased Progression-Free Survival (PFS) (HR 1.11 (95% CI\n1.03-1.21, p=0.009) in multivariate analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>EpCAM+ OC CTCs are phenotypically heterogeneous, which may reflect variability\nin their metastatic potential. CT changes the molecular characteristics of CTCs. Expression of\nTGF\u03b2 in EpCAM+ CTCs increases during CT. High ERCC1 expression in EpCAM+CK18+E-cadherin+\nCTCs during CT is associated with decreased PFS in OC.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009621666210720141229","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T19:32:15Z","timestamp":1626895935000},"page":"965-974","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Plasticity of Circulating Tumor Cells in Ovarian Cancer During Platinum-containing Chemotherapy"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6970-6659","authenticated-orcid":true,"given":"Snezhanna Olegovna","family":"Gening","sequence":"first","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, Faculty of Medicine, Ulyanovsk State University, Ulyanovsk,Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5475-7031","authenticated-orcid":true,"given":"Dinara Rishatovna","family":"Dolgova","sequence":"additional","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, Faculty of Medicine, Ulyanovsk State University, Ulyanovsk,Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7559-5246","authenticated-orcid":true,"given":"Tatyana Vladimirovna","family":"Abakumova","sequence":"additional","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, Faculty of Medicine, Ulyanovsk State University, Ulyanovsk,Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1525-2070","authenticated-orcid":true,"given":"Inna Ivanovna","family":"Antoneeva","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiation Diagnostics, Faculty of Medicine, Ulyanovsk State University, Ulyanovsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-1382","authenticated-orcid":true,"given":"Tatyana Petrovna","family":"Gening","sequence":"additional","affiliation":[{"name":"Department of Human Physiology and Pathophysiology, Faculty of Medicine, Ulyanovsk State University, Ulyanovsk,Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","volume":"12","author":"Cooke S.L.","year":"2011","unstructured":"Cooke S.L.; Brenton J.D.; Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 2011,12(12),1169-1174","journal-title":"Lancet Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","volume":"24","author":"Ledermann J.A.","year":"2013","unstructured":"Ledermann J.A.; Raja F.A.; Fotopoulou C.; Gonzalez-Martin A.; Colombo N.; Sessa C.; Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013,24(Suppl. 6),vi24-vi32","journal-title":"Ann Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13048-020-00691-y","volume":"13","author":"Beachler D.C.","year":"2020","unstructured":"Beachler D.C.; Lamy F-X.; Russo L.; Taylor D.H.; Dinh J.; Yin R.; Jamal-Allial A.; Dychter S.; Lanes S.; Verpillat P.; A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer. J Ovarian Res 2020,13(1),101","journal-title":"J Ovarian Res"},{"key":"ref=4","first-page":"40","volume":"25","author":"Kiss I.","year":"2020","unstructured":"Kiss I.; Kolostova K.; Pawlak I.; Bobek V.; Circulating tumor cells in gynaecological malignancies. J BUON 2020,25(1),40-50","journal-title":"J BUON"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41419-019-1795-7","volume":"10","author":"Liu T.","year":"2019","unstructured":"Liu T.; Ma Q.; Zhang Y.; Wang X.; Xu K.; Yan K.; Dong W.; Fan Q.; Zhang Y.; Qiu X.; Self-seeding circulating tumor cells promote the proliferation and metastasis of human osteosarcoma by upregulating interleukin-8. Cell Death Dis 2019,10(8),575","journal-title":"Cell Death Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1186\/s12885-017-3704-8","volume":"17","author":"Yang C.","year":"2017","unstructured":"Yang C.; Zou K.; Zheng L.; Xiong B.; Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: A meta-analysis and systematic review. BMC Cancer 2017,17(1),725","journal-title":"BMC Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e78070","DOI":"10.1371\/journal.pone.0078070","volume":"8","author":"Wang J.","year":"2013","unstructured":"Wang J.; Wang K.; Xu J.; Huang J.; Zhang T.; Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: A meta-analysis. PLoS One 2013,8(11),e78070","journal-title":"PLoS One"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1373\/clinchem.2013.215079","volume":"60","author":"Ramirez J-M.","year":"2014","unstructured":"Ramirez J-M.; Fehm T.; Orsini M.; Cayrefourcq L.; Maudelonde T.; Pantel K.; Alix-Panabi\u00e8res C.; Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem 2014,60(1),214-221","journal-title":"Clin Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"E1930","DOI":"10.3390\/cancers12071930","volume":"12","author":"Habli Z.","year":"2020","unstructured":"Habli Z.; AlChamaa W.; Saab R.; Kadara H.; Khraiche M.L.; Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities. Cancers (Basel) 2020,12(7),E1930","journal-title":"Cancers (Basel)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s00018-020-03529-4","volume":"77","author":"Mentis A.A.","year":"2020","unstructured":"Mentis A.A.; Grivas P.D.; Dardiotis E.; Romas N.A.; Papavassiliou A.G.; Circulating tumor cells as trojan horse for understanding, preventing, and treating cancer: A critical appraisal. Cell Mol Life Sci 2020,77(18),3671-3690","journal-title":"Cell Mol Life Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/bs.acc.2017.10.004","volume":"83","author":"Lowes L. E.","year":"2018","unstructured":"Lowes L. E.; Allan A. L.; Circulating tumor cells and implications of the epithelial-to-mesenchymal transition. 2018,83,121-181"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.21873\/anticanres.14345","volume":"40","author":"Tada H.","year":"2020","unstructured":"Tada H.; Takahashi H.; Ida S.; Nagata Y.; Chikamatsu K.; Epithelial\u2013mesenchymal transition status of circulating tumor cells is associated with tumor relapse in head and neck squamous cell carcinoma. Anticancer Res 2020,40(6),3559-3564","journal-title":"Anticancer Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00404-020-05477-7","volume":"301","author":"Banys-Paluchowski M.","year":"2020","unstructured":"Banys-Paluchowski M.; Fehm T.; Neubauer H.; Paluchowski P.; Krawczyk N.; Meier-Stiegen F.; Wallach C.; Kaczerowsky A.; Gebauer G.; Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer. Arch Gynecol Obstet 2020,301(4),1027-1035","journal-title":"Arch Gynecol Obstet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e15354","DOI":"10.1097\/MD.0000000000015354","volume":"98","author":"Kim M.","year":"2019","unstructured":"Kim M.; Suh D.H.; Choi J.Y.; Bu J.; Kang Y-T.; Kim K.; No J.H.; Kim Y.B.; Cho Y-H.; Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: A prospective observational study. Medicine (Baltimore) 2019,98(20),e15354","journal-title":"Medicine (Baltimore)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e0130873","DOI":"10.1371\/journal.pone.0130873","volume":"10","author":"Zhou Y.","year":"2015","unstructured":"Zhou Y.; Bian B.; Yuan X.; Xie G.; Ma Y.; Shen L.; Prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis. PLoS One 2015,10(6),e0130873","journal-title":"PLoS One"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","volume":"128","author":"Obermayr E.","year":"2013","unstructured":"Obermayr E.; Castillo-Tong D.C.; Pils D.; Speiser P.; Braicu I.; Van Gorp T.; Mahner S.; Sehouli J.; Vergote I.; Zeillinger R.; Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - a study of the OVCAD consortium. Gynecol Oncol 2013,128(1),15-21","journal-title":"Gynecol Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"E2398","DOI":"10.3390\/cancers12092398","volume":"12","author":"Guffanti F.","year":"2020","unstructured":"Guffanti F.; Alvisi M.F.; Caiola E.; Ricci F.; De Maglie M.; Soldati S.; Ganzinelli M.; Decio A.; Giavazzi R.; Rulli E.; Damia G.; Impact of ercc1, xpf and dna polymerase \u03b2 expression on platinum response in patient-derived ovarian cancer xenografts. Cancers (Basel) 2020,12(9),E2398","journal-title":"Cancers (Basel)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"E3145","DOI":"10.3390\/cancers12113145","volume":"12","author":"Ntellas P.","year":"2020","unstructured":"Ntellas P.; Mavroeidis L.; Gkoura S.; Gazouli I.; Amylidi A-L.; Papadaki A.; Zarkavelis G.; Mauri D.; Karpathiou G.; Kolettas E.; Batistatou A.; Pentheroudakis G.; Old player-new tricks: Non angiogenic effects of the vegf\/vegfr pathway in cancer. Cancers (Basel) 2020,12(11),E3145","journal-title":"Cancers (Basel)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"Lamouille S.","year":"2014","unstructured":"Lamouille S.; Xu J.; Derynck R.; Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014,15(3),178-196","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1002\/cam4.1783","volume":"7","author":"Zhang Z.","year":"2018","unstructured":"Zhang Z.; Tan X.; Luo J.; Cui B.; Lei S.; Si Z.; Shen L.; Yao H.; GNA13 promotes tumor growth and angiogenesis by upregulating CXC chemokines via the NF-\u03baB signaling pathway in colorectal cancer cells. Cancer Med 2018,7(11),5611-5620","journal-title":"Cancer Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1724600820963396","volume":"35","author":"Zhang C.","year":"2020","unstructured":"Zhang C.; Gao S.; Hou J.; ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis. Int J Biol Markers 2020,35(4),12-19","journal-title":"Int J Biol Markers"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ygyno.2012.11.002","volume":"128","author":"Yu L.","year":"2013","unstructured":"Yu L.; Deng L.; Li J.; Zhang Y.; Hu L.; The prognostic value of vascular endothelial growth factor in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol 2013,128(2),391-396","journal-title":"Gynecol Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e1111505","DOI":"10.1080\/2162402X.2015.1111505","volume":"5","author":"Coosemans A.","year":"2015","unstructured":"Coosemans A.; Decoene J.; Baert T.; Laenen A.; Kasran A.; Verschuere T.; Seys S.; Vergote I.; Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. OncoImmunology 2015,5(4),e1111505","journal-title":"OncoImmunology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.3390\/cancers11050668","volume":"11","author":"Roane B.M.","year":"2019","unstructured":"Roane B.M.; Arend R.C.; Birrer M.J.; Review: Targeting the transforming growth factor-beta pathway in ovarian cancer. Cancers (Basel) 2019,11(5),E668","journal-title":"Cancers (Basel)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2170606","DOI":"10.1155\/2020\/2170606","volume":"2020","author":"Zhou J.","year":"2020","unstructured":"Zhou J.; Jiang W.; Huang W.; Ye M.; Zhu X.; Prognostic values of transforming growth factor-beta subtypes in ovarian cancer. BioMed Res Int 2020,2020,2170606","journal-title":"BioMed Res Int"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"387382","DOI":"10.1155\/2015\/387382","volume":"2015","author":"Ye Q.","year":"2015","unstructured":"Ye Q.; Zhai X.; Wang W.; Zhang S.; Zhu H.; Wang D.; Wang C.; Overexpression of growth-related oncogene-\u03b2 is associated with tumorigenesis, metastasis, and poor prognosis in ovarian cancer. Dis Markers 2015,2015,387382","journal-title":"Dis Markers"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2020.03.013","volume":"479","author":"Takeyama Y.","year":"2020","unstructured":"Takeyama Y.; Kato M.; Tamada S.; Azuma Y.; Shimizu Y.; Iguchi T.; Yamasaki T.; Gi M.; Wanibuchi H.; Nakatani T.; Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer. Cancer Lett 2020,479,89-99","journal-title":"Cancer Lett"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","volume":"21","author":"Friedlander M.","year":"2011","unstructured":"Friedlander M.; Trimble E.; Tinker A.; Alberts D.; Avall-Lundqvist E.; Brady M.; Harter P.; Pignata S.; Pujade-Lauraine E.; Sehouli J.; Vergote I.; Beale P.; Bekkers R.; Calvert P.; Copeland L.; Glasspool R.; Gonzalez-Martin A.; Katsaros D.; Kim J.W.; Miller B.; Provencher D.; Rubinstein L.; Atri M.; Zeimet A.; Bacon M.; Kitchener H.; Stuart G.C.; Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer 2011,21(4),771-775","journal-title":"Int J Gynecol Cancer"},{"key":"ref=29","first-page":"2522923","author":"Zubtsov D.A.","year":"2014","unstructured":"Zubtsov D.A.; Zubtsova Z.I.; Legchenko E.V.; Lavrov A.V.; Goldstein D.V.; Comprehensive method for determining circulating tumor cells in the blood of breast cancer patients. 2014,2522923"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"Livak K.J.","year":"2001","unstructured":"Livak K.J.; Schmittgen T.D.; Analysis of relative gene expression data using real-time quantitative PCR and the 2(-\u0394 \u0394 C(T)) Method. Methods 2001,25(4),402-408","journal-title":"Methods"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ygyno.2017.10.032","volume":"148","author":"Hoppenot C.","year":"2018","unstructured":"Hoppenot C.; Eckert M.A.; Tienda S.M.; Lengyel E.; Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol 2018,148(1),204-212","journal-title":"Gynecol Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.neo.2017.04.002","volume":"19","author":"Klymenko Y.","year":"2017","unstructured":"Klymenko Y.; Johnson J.; Bos B.; Lombard R.; Campbell L.; Loughran E.; Stack M.S.; Heterogeneous cadherin expression and multicellular aggregate dynamics in ovarian cancer dissemination. Neoplasia 2017,19(7),549-563","journal-title":"Neoplasia"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.molonc.2016.04.002","volume":"10","author":"Blassl C.","year":"2016","unstructured":"Blassl C.; Kuhlmann J.D.; Webers A.; Wimberger P.; Fehm T.; Neubauer H.; Gene expression profiling of single circulating tumor cells in\u00a0ovarian cancer - establishment of a multi-marker gene panel. Mol Oncol 2016,10(7),1030-1042","journal-title":"Mol Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e915","DOI":"10.1038\/cddis.2013.442","volume":"4","author":"Huang R.Y-J.","year":"2013","unstructured":"Huang R.Y-J.; Wong M.K.; Tan T.Z.; Kuay K.T.; Ng A.H.C.; Chung V.Y.; Chu Y-S.; Matsumura N.; Lai H-C.; Lee Y.F.; Sim W-J.; Chai C.; Pietschmann E.; Mori S.; Low J.J.H.; Choolani M.; Thiery J.P.; An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis 2013,4(11),e915","journal-title":"Cell Death Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/cas.14285","volume":"111","author":"Quan Q.","year":"2020","unstructured":"Quan Q.; Wang X.; Lu C.; Ma W.; Wang Y.; Xia G.; Wang C.; Yang G.; Cancer stem-like cells with hybrid epithelial\/mesenchymal phenotype leading the collective invasion. Cancer Sci 2020,111(2),467-476","journal-title":"Cancer Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"E4992","DOI":"10.3390\/ijms21144992","volume":"21","author":"Mehdi S.","year":"2020","unstructured":"Mehdi S.; Macdonald E.; Galpin K.; Landry D.A.; Rodriguez G.; Vanderhyden B.; Bachvarov D.; LY75 suppression in mesenchymal epithelial ovarian cancer cells generates a stable hybrid eoc cellular phenotype, associated with enhanced tumor initiation, spreading and resistance to treatment in orthotopic xenograft mouse model. Int J Mol Sci 2020,21(14),E4992","journal-title":"Int J Mol Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"E1218","DOI":"10.3390\/cells9051218","volume":"9","author":"Abreu M.","year":"2020","unstructured":"Abreu M.; Cabezas-Sainz P.; Alonso-Alconada L.; Ferreir\u00f3s A.; Mondelo-Mac\u00eda P.; Lago-Lest\u00f3n R.M.; Abalo A.; D\u00edaz E.; Palacios-Zambrano S.; Rojo-Sebastian A.; L\u00f3pez-L\u00f3pez R.; S\u00e1nchez L.; Moreno-Bueno G.; Muinelo-Romay L.; Circulating tumor cells characterization revealed timp1 as a potential therapeutic target in ovarian cancer. Cells 2020,9(5),E1218","journal-title":"Cells"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","volume":"46","author":"Fabregat A.","year":"2018","unstructured":"Fabregat A.; Jupe S.; Matthews L.; Sidiropoulos K.; Gillespie M.; Garapati P.; Haw R.; Jassal B.; Korninger F.; May B.; Milacic M.; Roca C.D.; Rothfels K.; Sevilla C.; Shamovsky V.; Shorser S.; Varusai T.; Viteri G.; Weiser J.; Wu G.; Stein L.; Hermjakob H.; D\u2019Eustachio P.; The reactome pathway knowledgebase. Nucleic Acids Res 2018,46(D1),D649-D655","journal-title":"Nucleic Acids Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/imammb\/dqq011","volume":"29","author":"Hatzikirou H.","year":"2012","unstructured":"Hatzikirou H.; Basanta D.; Simon M.; Schaller K.; Deutsch A.; \u2018Go or grow\u2019: The key to the emergence of invasion in tumour progression? Math Med Biol 2012,29(1),49-65","journal-title":"Math Med Biol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.4081\/oncol.2020.475","volume":"14","author":"Roque R.","year":"2020","unstructured":"Roque R.; Costa Sousa F.; Figueiredo-Dias M.; Epithelial-mesenchymal interconversions in ovarian cancer: The levels and functions of E-cadherin in intraabdominal dissemination. Oncol Rev 2020,14(2),475","journal-title":"Oncol Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/s41467-018-03966-7","volume":"9","author":"Taki M.","year":"2018","unstructured":"Taki M.; Abiko K.; Baba T.; Hamanishi J.; Yamaguchi K.; Murakami R.; Yamanoi K.; Horikawa N.; Hosoe Y.; Nakamura E.; Sugiyama A.; Mandai M.; Konishi I.; Matsumura N.; Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun 2018,9(1),1685","journal-title":"Nat Commun"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1002\/jcb.24191","volume":"113","author":"Kavandi L.","year":"2012","unstructured":"Kavandi L.; Collier M.A.; Nguyen H.; Syed V.; Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells. J Cell Biochem 2012,113(10),3143-3152","journal-title":"J Cell Biochem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"304","DOI":"10.15252\/emmm.201606840","volume":"9","author":"Jang K.","year":"2017","unstructured":"Jang K.; Kim M.; Gilbert C.A.; Simpkins F.; Ince T.A.; Slingerland J.M.; VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells. EMBO Mol Med 2017,9(3),304-318","journal-title":"EMBO Mol Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s13402-020-00513-9","volume":"43","author":"Yousefi M.","year":"2020","unstructured":"Yousefi M.; Dehghani S.; Nosrati R.; Ghanei M.; Salmaninejad A.; Rajaie S.; Hasanzadeh M.; Pasdar A.; Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles. Cell Oncol (Dordr) 2020,43(4),515-538","journal-title":"Cell Oncol (Dordr)"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e0240833","DOI":"10.1371\/journal.pone.0240833","volume":"15","author":"Sarkar S.","year":"2020","unstructured":"Sarkar S.; Peng C-C.; Tung Y-C.; Comparison of VEGF-A secretion from tumor cells under cellular stresses in conventional monolayer culture and microfluidic three-dimensional spheroid models. PLoS One 2020,15(11),e0240833","journal-title":"PLoS One"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.trecan.2018.10.010","volume":"5","author":"Prunier C.","year":"2019","unstructured":"Prunier C.; Baker D.; Ten Dijke P.; Ritsma L.; TGF-\u03b2 family signaling pathways in cellular dormancy. Trends Cancer 2019,5(1),66-78","journal-title":"Trends Cancer"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1038\/s41467-020-19408-2","volume":"11","author":"Desbois M.","year":"2020","unstructured":"Desbois M.; Udyavar A.R.; Ryner L.; Kozlowski C.; Guan Y.; D\u00fcrrbaum M.; Lu S.; Fortin J-P.; Koeppen H.; Ziai J.; Chang C-W.; Keerthivasan S.; Plante M.; Bourgon R.; Bais C.; Hegde P.; Daemen A.; Turley S.; Wang Y.; Integrated digital pathology and transcriptome analysis identifies molecular mediators of T- cell exclusion in ovarian cancer. Nat Commun 2020,11(1),5583","journal-title":"Nat Commun"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","volume":"60","author":"Kuhlmann J.D.","year":"2014","unstructured":"Kuhlmann J.D.; Wimberger P.; Bankfalvi A.; Keller T.; Sch\u00f6ler S.; Aktas B.; Buderath P.; Hauch S.; Otterbach F.; Kimmig R.; Kasimir-Bauer S.; ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem 2014,60(10),1282-1289","journal-title":"Clin Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"24303","DOI":"10.18632\/oncotarget.13286","volume":"8","author":"Chebouti I.","year":"2017","unstructured":"Chebouti I.; Kuhlmann J.D.; Buderath P.; Weber S.; Wimberger P.; Bokeloh Y.; Hauch S.; Kimmig R.; Kasimir-Bauer S.; ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer. Oncotarget 2017,8(15),24303-24313","journal-title":"Oncotarget"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00262-018-2249-2","volume":"68","author":"Gershkovitz M.","year":"2019","unstructured":"Gershkovitz M.; Fainsod-Levi T.; Zelter T.; Sionov R.V.; Granot Z.; TRPM2 modulates neutrophil attraction to murine tumor cells by regulating CXCL2 expression. Cancer Immunol Immunother 2019,68(1),33-43","journal-title":"Cancer Immunol Immunother"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/1354750X.2020.1783574","volume":"25","author":"Micheli D.C.","year":"2020","unstructured":"Micheli D.C.; Jammal M.P.; Martins-Filho A.; C\u00f4rtes J.R.X.M.; Souza C.N.; Nomelini R.S.; Murta E.F.C.; Tavares- Murta B.M.; Serum cytokines and CXCR2: Potential tumour markers in ovarian neoplasms. Biomarkers 2020,25(6),474-482","journal-title":"Biomarkers"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1158\/0008-5472.CAN-19-1972","volume":"79","author":"Saini M.","year":"2019","unstructured":"Saini M.; Szczerba B.M.; Aceto N.; Circulating tumor cell-neutrophil tango along the metastatic process. Cancer Res 2019,79(24),6067-6073","journal-title":"Cancer Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/cncr.31935","volume":"125","author":"Mao W.","year":"2019","unstructured":"Mao W.; Peters H.L.; Sutton M.N.; Orozco A.F.; Pang L.; Yang H.; Lu Z.; Bast R.C.; The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts. Cancer 2019,125(8),1267-1280","journal-title":"Cancer"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"8161","DOI":"10.2147\/OTT.S250392","volume":"13","author":"Li X.","year":"2020","unstructured":"Li X.; Hu Z.; Shi H.; Wang C.; Lei J.; Cheng Y.; Inhibition of vegfa increases the sensitivity of ovarian cancer cells to chemotherapy by suppressing vegfa-mediated autophagy. OncoTargets Ther 2020,13,8161-8171","journal-title":"OncoTargets Ther"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/194933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194933\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/194933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T06:34:43Z","timestamp":1648449283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194933\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009621666210720141229","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}